Sound Bioventures
VC Fund
Malmö, Sweden
Sound Bioventures is a venture capital fund investing in clinical stage companies.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 57%
- Fund size:
- $124M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sound Bioventures invests in
Stages Sound Bioventures invests in
Countries Sound Bioventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $18M–$83M
- Series B
- $37M–$71M
- Venture - Series Unknown
- $3.6M–$26M
Investment Focus
Industry
- Biotechnology 7 (50%)
- Medical 6 (43%)
- Therapeutics 5 (36%)
- Biopharma 4 (29%)
- Life Science 2 (14%)
Stage
- Series A 5 (36%)
- Series B 3 (21%)
- Venture - Series Unknown 3 (21%)
- Seed 1 (7%)
- Convertible Note 1 (7%)
Country
- Denmark 2 (14%)
- United States 2 (14%)
- United Kingdom 2 (14%)
- Spain 1 (7%)
- France 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Johan Kördel
Managing Partner
|
Managing Partner | Total investments: 21 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | $70.8M / Series B / Sep 30, 2026 | ||
| Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases. | $76.7M / Series A / Sep 29, 2026 | ||
| Cytospire Therapeutics is bringing forward a portfolio of next generation immune cell engagers. | $82.6M / Series A / May 05, 2026 | ||
| BOOST Pharma is a biotechnology research company developing a stem cell therapy for the treatment of osteogenesis imperfecta. It is based on novel mesenchymal stem cells that have high bone-forming capabilities that migrate to the bone of patients where they will engraft, and start bone formation.It was founded in 2019 and is headquartered inCopenhagen, Denmark. | $3.6M / Venture - Series Unknown / Nov 03, 2025 | ||
| ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successfuldevelopment of our products. | $40.6M / Series B / Sep 17, 2025 | ||
| AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | $18.4M / Series A / Jan 09, 2025 | ||
| Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.The companywas founded in 2013 and is headquartered in Cambridge, Massachusetts. | $8M / Convertible Note / Aug 06, 2024 | ||
| Theolytics is a clinical stage biotechnology company harnessing viruses to combat disease. A step-change in the adenoviral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition toadvancing an internal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development. | $23.7M / Venture - Series Unknown / Apr 17, 2024 | ||
| AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M / Series A / Sep 18, 2023 | ||
| VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $37M / Series B / May 25, 2023 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sound Bioventures invest in?
Sound Bioventures invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Sound Bioventures invest in?
Sound Bioventures typically joins rounds of $18M–$83M at Series A, $37M–$71M at Series B and $3.6M–$26M at Venture - Series Unknown. These are whole funding-round sizes, not Sound Bioventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Sound Bioventures took part in.
How do I contact Sound Bioventures?
Public channels for Sound Bioventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sound Bioventures?
The team at Sound Bioventures includes Johan Kördel (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
